Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Cytokinetics (CYTK)

Cytokinetics (CYTK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 7,478,458
  • Shares Outstanding, K 123,163
  • Annual Sales, $ 88,040 K
  • Annual Income, $ -784,960 K
  • EBIT $ -612 M
  • EBITDA $ -602 M
  • 60-Month Beta 0.56
  • Price/Sales 85.94
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 82.11% (-2.97%)
  • Historical Volatility 46.08%
  • IV Percentile 84%
  • IV Rank 55.88%
  • IV High 110.92% on 04/09/25
  • IV Low 45.63% on 06/09/25
  • Expected Move (DTE 16) 4.75 (7.63%)
  • Put/Call Vol Ratio 0.07
  • Today's Volume 1,117
  • Volume Avg (30-Day) 3,118
  • Put/Call OI Ratio 0.23
  • Today's Open Interest 100,833
  • Open Int (30-Day) 85,985
  • Expected Range 57.52 to 67.02

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 21 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate -1.64
  • Number of Estimates 9
  • High Estimate -1.26
  • Low Estimate -1.86
  • Prior Year -1.36
  • Growth Rate Est. (year over year) -20.59%

Price Performance

See More
Period Period Low Period High Performance
1-Month
59.33 +4.96%
on 03/03/26
70.39 -11.54%
on 02/24/26
-1.25 (-1.97%)
since 02/04/26
3-Month
58.85 +5.81%
on 01/05/26
70.98 -12.27%
on 12/22/25
-4.27 (-6.42%)
since 12/04/25
52-Week
29.31 +112.45%
on 05/15/25
70.98 -12.27%
on 12/22/25
+18.58 (+42.53%)
since 03/04/25

Most Recent Stories

More News
Cytokinetics to Participate in March Investor Conferences

SOUTH SAN FRANCISCO, Calif., March 02, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that members of the Company management team will participate in the following...

CYTK : 62.27 (+2.55%)
Cytokinetics: Q4 Earnings Snapshot

Cytokinetics: Q4 Earnings Snapshot

CYTK : 62.27 (+2.55%)
Cytokinetics Reports Fourth Quarter 2025 Financial Results and Provides Business Update

MYQORZO® Approved for Adults with Symptomatic Obstructive HCM in U.S., China and Europe;  U.S. Launch Underway with First Prescriptions Dispensed within Days of Drug Availability Supplemental...

CYTK : 62.27 (+2.55%)
Cytokinetics Announces European Commission Approval of MYQORZO® (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy

European Commission Approval Based on Results of SEQUOIA-HCM First European Launch Expected in Germany in Q2 2026 SOUTH SAN FRANCISCO, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Cytokinetics,...

CYTK : 62.27 (+2.55%)
Cytokinetics to Announce Fourth Quarter Results on February 24, 2026

SOUTH SAN FRANCISCO, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report fourth quarter results on February 24, 2026 at...

CYTK : 62.27 (+2.55%)
Cytokinetics Announces Recipients of Its Eighth Annual Communications Grant Program

Grants Awarded to Two Patient Advocacy Organizations  to Support Communications and Community Outreach SOUTH SAN FRANCISCO, Calif., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated...

CYTK : 62.27 (+2.55%)
Cytokinetics and Olympic Gold Medalist Sydney McLaughlin-Levrone Team Up to Raise Awareness of the Whole-Person Impact of Hypertrophic Cardiomyopathy (HCM)

“On Track with HCM” Features Practical Insights for Managing Everyday Life with the Disease, Inspired by the Experience with HCM of McLaughlin-Levrone’s Father, Willie McLaughlin SOUTH SAN...

CYTK : 62.27 (+2.55%)
Cytokinetics Announces MYQORZO™ (aficamten) Now Available in the U.S. for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and Symptoms

MYQORZO, a Cardiac Myosin Inhibitor, Directly Addresses Underlying  Hypercontractility Associated with Obstructive HCM SOUTH SAN FRANCISCO, Calif., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Cytokinetics,...

CYTK : 62.27 (+2.55%)
The Law Offices of Frank R. Cruz Announces Investigation of Cytokinetics, Incorporated (CYTK) on Behalf of Investors

The Law Offices of Frank R. Cruz is investigating potential claims against the board of directors of Cytokinetics, Incorporated (“Cytokinetics” or the “Company”) (NASDAQ: CYTK ...

CYTK : 62.27 (+2.55%)
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on January 15, 2026 it granted stock options to purchase an aggregate of...

CYTK : 62.27 (+2.55%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or deteriorating. With an unmatched understanding of muscle biology...

See More

Key Turning Points

3rd Resistance Point 65.78
2nd Resistance Point 64.18
1st Resistance Point 63.22
Last Price 62.27
1st Support Level 60.66
2nd Support Level 59.06
3rd Support Level 58.10

See More

52-Week High 70.98
Last Price 62.27
Fibonacci 61.8% 55.06
Fibonacci 50% 50.15
Fibonacci 38.2% 45.23
52-Week Low 29.31

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar